Kenichi Hirabayashi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kenichi Hirabayashi has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
Aya Kawanishi
Department of Gastroenterology and Hepatology, Tokai University School of Medicine, Isehara, Japan
2 shared publications- Isaku Yoshioka
Department of Surgery and Science, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan
2 shared publications - Isaya Hashimoto
Department of Surgery and Science, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama 9300194, Japan
2 shared publications - Katsuhisa Hirano
Department of Surgery and Science, Faculty of Medicine, Academic Assembly University of Toyama Toyama Japan
2 shared publications - Kazuto Shibuya
Department of Surgery and Science, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan
2 shared publications - Kohji Takagi
Department of Diagnostic Pathology, University of Toyama, Toyama, Japan
2 shared publications
Latest Publications
- Open Access
- 12 June 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (24) , e49220
Cytoplasmic expression of laminin-5γ2 chain is associated with progression and acquisition of malignant traits in ovarian serous and mucinous tumors
Ovarian tumors are classified into adenoma, borderline tumor, and adenocarcinoma based on cellular atypia and invasion. However, invasion can be difficult to assess histologically, underscoring the need for objective biomarkers. Laminin-5γ2 chain (Lam5γ2), a component of the basement membrane, has been implicated in tumor cell invasion in various malignancies. This study aimed to investigate the immunohistochemical expression of Lam5γ2 as a potential adjunctive biomarker associated with invasive phenotypes in ovarian serous and mucinous tumors. Lam5γ2 immunohistochemistry was performed on 80 ovarian tumor specimens, including adenomas, borderline tumors, and adenocarcinomas of serous and mucinous subtypes. Lam5γ2 expression patterns were compared across histological categories. In serous tumors, Lam5γ2 expression along the basement membrane was preserved in approximately half of adenomas and borderline tumors but was absent in all adenocarcinomas. Notably, cytoplasmic expression was observed in 11 of 12 serous adenocarcinomas (92%), and cytoplasmic staining was more frequent in borderline tumors and adenocarcinomas than in adenomas. A similar pattern was observed in mucinous tumors, with a decrease in basement membrane expression from adenomas to borderline tumors to adenocarcinomas. In mucinous adenocarcinomas, cytoplasmic expression was present in 6 of 10 cases, while basement membrane linear expression was retained in 3 of 10 cases. These differences were statistically significant in both serous and mucinous tumors ( P <.001 and P = .03, respectively). Loss of Lam5γ2 expression from the basement membrane and aberrant cytoplasmic localization in ovarian serous and mucinous tumor cells were associated with histological progression and invasive phenotypes. Thus, Lam5γ2 immunoreactivity may serve as a potential adjunctive biomarker, particularly in diagnostically challenging borderline or microinvasive cases, pending validation in larger, independent cohorts.
- 12 June 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (24) , e49220
Open AccessCytoplasmic expression of laminin-5γ2 chain is associated with progression and acquisition of malignant traits in ovarian serous and mucinous tumors
Ovarian tumors are classified into adenoma, borderline tumor, and adenocarcinoma based on cellular atypia and invasion. However, invasion can be difficult to assess histologically, underscoring the need for objective biomarkers. Laminin-5γ2 chain (Lam5γ2), a component of the basement membrane, has been implicated in tumor cell invasion in various malignancies. This study aimed to investigate the immunohistochemical expression of Lam5γ2 as a potential adjunctive biomarker associated with invasive phenotypes in ovarian serous and mucinous tumors. Lam5γ2 immunohistochemistry was performed on 80 ovarian tumor specimens, including adenomas, borderline tumors, and adenocarcinomas of serous and mucinous subtypes. Lam5γ2 expression patterns were compared across histological categories. In serous tumors, Lam5γ2 expression along the basement membrane was preserved in approximately half of adenomas and borderline tumors but was absent in all adenocarcinomas. Notably, cytoplasmic expression was observed in 11 of 12 serous adenocarcinomas (92%), and cytoplasmic staining was more frequent in borderline tumors and adenocarcinomas than in adenomas. A similar pattern was observed in mucinous tumors, with a decrease in basement membrane expression from adenomas to borderline tumors to adenocarcinomas. In mucinous adenocarcinomas, cytoplasmic expression was present in 6 of 10 cases, while basement membrane linear expression was retained in 3 of 10 cases. These differences were statistically significant in both serous and mucinous tumors ( P <.001 and P = .03, respectively). Loss of Lam5γ2 expression from the basement membrane and aberrant cytoplasmic localization in ovarian serous and mucinous tumor cells were associated with histological progression and invasive phenotypes. Thus, Lam5γ2 immunoreactivity may serve as a potential adjunctive biomarker, particularly in diagnostically challenging borderline or microinvasive cases, pending validation in larger, independent cohorts.
- 26 August 2025
- Published by Springer Nature in International Cancer Conference Journal
- Vol. 14 (4) , 464-471
A case of successfully completed robot-assisted distal pancreatectomy for pancreatic tail cancer in a patient with prior colostomy: case report
Introduction Pancreatic cancer may invade the colon, resulting in bowel obstruction and requiring the patient to undergo colostomy. Open surgery is often the treatment of choice for patients with colostomy, but we successfully and safely performed a robot-assisted distal pancreatectomy. Case presentation The patient was a 55-year-old woman diagnosed with pancreatic tail cancer invading the left kidney and transverse colon. She underwent a transverse colostomy because of a colonic obstruction associated with colon invasion. She then received gemcitabine plus nab-paclitaxel, followed by modified FOLFIRINOX. After imaging confirmed tumour shrinkage, a robot-assisted distal pancreatectomy, transverse colon resection, and colostomy closure were planned. A partial colon resection, including colostomy, was performed first. As a result, robot-assisted surgery was possible with the usual field of view and port placement. During this procedure, the pancreatic tail, spleen, transverse colon (including invasive pancreatic cancer lesion), left adrenal gland, and part of the left kidney were resected en bloc. Finally, reconstruction of the colon was performed. The patient recovered well postoperatively and was discharged on postoperative day 9 with no complications. The patient has been recurrence-free for 2 months after surgery. Conclusion This case demonstrates that robot-assisted distal pancreatectomy is feasible in selected patients with pancreatic cancer and prior colostomy.
- 26 August 2025
- Published by Springer Nature in International Cancer Conference Journal
- Vol. 14 (4) , 464-471
A case of successfully completed robot-assisted distal pancreatectomy for pancreatic tail cancer in a patient with prior colostomy: case report
Introduction Pancreatic cancer may invade the colon, resulting in bowel obstruction and requiring the patient to undergo colostomy. Open surgery is often the treatment of choice for patients with colostomy, but we successfully and safely performed a robot-assisted distal pancreatectomy. Case presentation The patient was a 55-year-old woman diagnosed with pancreatic tail cancer invading the left kidney and transverse colon. She underwent a transverse colostomy because of a colonic obstruction associated with colon invasion. She then received gemcitabine plus nab-paclitaxel, followed by modified FOLFIRINOX. After imaging confirmed tumour shrinkage, a robot-assisted distal pancreatectomy, transverse colon resection, and colostomy closure were planned. A partial colon resection, including colostomy, was performed first. As a result, robot-assisted surgery was possible with the usual field of view and port placement. During this procedure, the pancreatic tail, spleen, transverse colon (including invasive pancreatic cancer lesion), left adrenal gland, and part of the left kidney were resected en bloc. Finally, reconstruction of the colon was performed. The patient recovered well postoperatively and was discharged on postoperative day 9 with no complications. The patient has been recurrence-free for 2 months after surgery. Conclusion This case demonstrates that robot-assisted distal pancreatectomy is feasible in selected patients with pancreatic cancer and prior colostomy.
- Open Access
- 2 August 2023
- Published by Springer Nature in Surgical Case Reports
- Vol. 9 (1) , 1-5
A case of squamous cell carcinoma of the breast achieved a pathological complete response after dose-dense AC + dose-dense PTX
Background: Squamous cell carcinoma (SCC) of the breast is a rare form of breast cancer, accounting for approximately 0.1% of all breast cancers. It is known for its rapid tumor growth and poor prognosis with no established treatment. Case presentation: A 56-year-old woman was diagnosed with breast SCC with axillary, supraclavicular and internal thoracic lymph node metastases. She received neoadjuvant chemotherapy (NAC) with dose-dense doxorubicin and cyclophosphamide (AC) followed by dose-dense paclitaxel (PTX). This treatment resulted in a pathological complete response (pCR) after breast-conserving surgery. The patient was then treated with radiotherapy. She remained free of recurrence for three years postoperatively. Conclusions: We report a rare case of breast SCC treated with preoperative dose-dense chemotherapy, resulting in pCR and allowing breast-conserving surgery.
- 2 August 2023
- Published by Springer Nature in Surgical Case Reports
- Vol. 9 (1) , 1-5
Open AccessA case of squamous cell carcinoma of the breast achieved a pathological complete response after dose-dense AC + dose-dense PTX
Background: Squamous cell carcinoma (SCC) of the breast is a rare form of breast cancer, accounting for approximately 0.1% of all breast cancers. It is known for its rapid tumor growth and poor prognosis with no established treatment. Case presentation: A 56-year-old woman was diagnosed with breast SCC with axillary, supraclavicular and internal thoracic lymph node metastases. She received neoadjuvant chemotherapy (NAC) with dose-dense doxorubicin and cyclophosphamide (AC) followed by dose-dense paclitaxel (PTX). This treatment resulted in a pathological complete response (pCR) after breast-conserving surgery. The patient was then treated with radiotherapy. She remained free of recurrence for three years postoperatively. Conclusions: We report a rare case of breast SCC treated with preoperative dose-dense chemotherapy, resulting in pCR and allowing breast-conserving surgery.
- Open Access
- 26 October 2022
- Published by Springer Nature in Scientific Reports
- Vol. 12 (1) , 1-12
miR-4653-3p overexpression is associated with a poor prognosis of pancreatic ductal adenocarcinoma via HIPK2 downregulation
Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignant tumor. Several upregulated and downregulated microRNAs (miRNAs) are associated with invasiveness, tumorigenesis, and prognosis of PDAC. Herein, using in situ hybridization, we evaluated miR-4653-3p expression and pancreatic intraepithelial neoplasia (PanIN) and the association between miR-4653-3p expression and clinicopathological factors in PDAC patients. The miR-4653-3p target was also identified. Ninety PDAC cases, including 30 each with normal pancreatic ducts, low-grade PanINs, and high-grade PanINs, were evaluated. miR-4653-3p expression increased in the order—normal pancreatic duct, low-grade PanIN, high-grade PanIN, and PDAC—with no expression detected in normal pancreatic duct. High expression significantly correlated with advanced pathological T stage, lymph node metastasis, advanced Union for International Cancer Control stage, perineural invasion, venous involvement, and shorter overall and disease-specific survival. Homeodomain Interacting Protein Kinase 2 (HIPK2) was identified as a miR-4653-3p target based on mRNA microarray analysis and database screening. In MIA PaCa-2 cells, miR-4653-3p significantly downregulated HIPK2 expression. HIPK2 expression, unlike that of miR-4653-3p, decreased in the order—normal pancreatic duct, low-grade PanIN, high-grade PanIN, and PDAC. Low HIPK2 expression was associated with shorter overall and disease-specific survival in PDAC patients. Thus, miR-4653-3p associates with tumorigenesis and worse prognosis, partly by reducing HIPK2 expression.
- 26 October 2022
- Published by Springer Nature in Scientific Reports
- Vol. 12 (1) , 1-12
Open AccessmiR-4653-3p overexpression is associated with a poor prognosis of pancreatic ductal adenocarcinoma via HIPK2 downregulation
Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignant tumor. Several upregulated and downregulated microRNAs (miRNAs) are associated with invasiveness, tumorigenesis, and prognosis of PDAC. Herein, using in situ hybridization, we evaluated miR-4653-3p expression and pancreatic intraepithelial neoplasia (PanIN) and the association between miR-4653-3p expression and clinicopathological factors in PDAC patients. The miR-4653-3p target was also identified. Ninety PDAC cases, including 30 each with normal pancreatic ducts, low-grade PanINs, and high-grade PanINs, were evaluated. miR-4653-3p expression increased in the order—normal pancreatic duct, low-grade PanIN, high-grade PanIN, and PDAC—with no expression detected in normal pancreatic duct. High expression significantly correlated with advanced pathological T stage, lymph node metastasis, advanced Union for International Cancer Control stage, perineural invasion, venous involvement, and shorter overall and disease-specific survival. Homeodomain Interacting Protein Kinase 2 (HIPK2) was identified as a miR-4653-3p target based on mRNA microarray analysis and database screening. In MIA PaCa-2 cells, miR-4653-3p significantly downregulated HIPK2 expression. HIPK2 expression, unlike that of miR-4653-3p, decreased in the order—normal pancreatic duct, low-grade PanIN, high-grade PanIN, and PDAC. Low HIPK2 expression was associated with shorter overall and disease-specific survival in PDAC patients. Thus, miR-4653-3p associates with tumorigenesis and worse prognosis, partly by reducing HIPK2 expression.
- Open Access
- 1 October 2022
- Published by Wolters Kluwer Health in Pancreas
- Vol. 51 (9) , 1105-1111
Diagnostic Categories and Key Features for Pathological Diagnosis of Endoscopic Ultrasound-Guided Fine Needle Aspiration Biopsy Samples of Pancreatic Lesions
Objectives: This study aimed to establish a reliable and reproducible categorized diagnostic classification system with identification of key features to achieve accurate pathological diagnosis of endoscopic ultrasound-guided fine needle aspiration biopsy (EUS-FNAB) samples of pancreatic lesions. Methods: Twelve pathologists examined virtual whole-slide images of EUS-FNAB samples obtained from 80 patients according to proposed diagnostic categories and key features for diagnosis. Fleiss κ was used to assess the concordance. Results: A hierarchical diagnostic system consisting of the following 6 diagnostic categories was proposed: inadequate, nonneoplasm, indeterminate, ductal carcinoma, nonductal neoplasm, and unclassified neoplasm. Adopting these categories, the average κ value of participants was 0.677 (substantial agreement). Among these categories, ductal carcinoma and nonductal neoplasm showed high κ values of 0.866 and 0.837, respectively, which indicated the almost perfect agreement. Key features identified for diagnosing ductal carcinoma were necrosis in low-power appearance; structural atypia/abnormalities recognized by irregular glandular contours, including cribriform and nonuniform shapes; cellular atypia, including enlarged nuclei, irregular nuclear contours, and foamy gland changes; and haphazard glandular arrangement and stromal desmoplasia. Conclusions: The proposed hierarchical diagnostic classification system was proved to be useful for achieving reliable and reproducible diagnosis of EUS-FNAB specimens of pancreatic lesions based on evaluated histological features.
- 1 October 2022
- Published by Wolters Kluwer Health in Pancreas
- Vol. 51 (9) , 1105-1111
Open AccessDiagnostic Categories and Key Features for Pathological Diagnosis of Endoscopic Ultrasound-Guided Fine Needle Aspiration Biopsy Samples of Pancreatic Lesions
Objectives: This study aimed to establish a reliable and reproducible categorized diagnostic classification system with identification of key features to achieve accurate pathological diagnosis of endoscopic ultrasound-guided fine needle aspiration biopsy (EUS-FNAB) samples of pancreatic lesions. Methods: Twelve pathologists examined virtual whole-slide images of EUS-FNAB samples obtained from 80 patients according to proposed diagnostic categories and key features for diagnosis. Fleiss κ was used to assess the concordance. Results: A hierarchical diagnostic system consisting of the following 6 diagnostic categories was proposed: inadequate, nonneoplasm, indeterminate, ductal carcinoma, nonductal neoplasm, and unclassified neoplasm. Adopting these categories, the average κ value of participants was 0.677 (substantial agreement). Among these categories, ductal carcinoma and nonductal neoplasm showed high κ values of 0.866 and 0.837, respectively, which indicated the almost perfect agreement. Key features identified for diagnosing ductal carcinoma were necrosis in low-power appearance; structural atypia/abnormalities recognized by irregular glandular contours, including cribriform and nonuniform shapes; cellular atypia, including enlarged nuclei, irregular nuclear contours, and foamy gland changes; and haphazard glandular arrangement and stromal desmoplasia. Conclusions: The proposed hierarchical diagnostic classification system was proved to be useful for achieving reliable and reproducible diagnosis of EUS-FNAB specimens of pancreatic lesions based on evaluated histological features.
- Open Access
- 6 June 2022
- Published by Springer Nature in Research Square
miR-4653-3p overexpression is associated with a poor prognosis of pancreatic ductal adenocarcinoma via HIPK2 downregulation
Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignant tumor. Several upregulated or downregulated microRNAs (miRNAs) are associated with invasiveness, tumorigenesis, and prognosis of PDAC. This study evaluated miR-4653-3p expression and pancreatic intraepithelial neoplasia (PanIN) using in situ hybridization and the association between miR-4653-3p expression and clinicopathological factors in patients with PDAC. The miR-4653-3p target was also identified. Ninety PDAC cases, including 30 normal pancreatic ducts, 30 low-grade PanINs, and 30 high-grade PanINs were evaluated. miR-4653-3p expression was absent in normal pancreatic ducts and increased in the following order: normal pancreatic duct, low-grade PanIN, high-grade PanIN, and PDAC. High miR-4653-3p expression significantly correlated with advanced pathological T stage, lymph node metastasis, advanced UICC stage, perineural invasion, venous involvement, and shorter overall survival. Homeodomain Interacting Protein Kinase 2 (HIPK2) was identified as a miR-4653-3p target based on mRNA microarray analysis and database screening. In vitro analysis using pancreatic cancer cells showed that miR-4653-3p significantly downregulated HIPK2 expression. Immunohistochemical analysis showed that HIPK2 expression inversely correlated with miR-4653-3p expression in PDAC surgical specimens. In contrast to miR-4653-3p, HIPK2 expression decreased gradually from the normal pancreatic duct to low-grade PanIN, high-grade PanIN, and PDAC. Additionally, low HIPK2 expression was associated with shorter overall survival in patients with PDAC. These results indicate that miR-4653-3p is associated with tumorigenesis and a worse prognosis, partly by reducing HIPK2 expression.
- 6 June 2022
- Published by Springer Nature in Research Square
Open AccessmiR-4653-3p overexpression is associated with a poor prognosis of pancreatic ductal adenocarcinoma via HIPK2 downregulation
Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignant tumor. Several upregulated or downregulated microRNAs (miRNAs) are associated with invasiveness, tumorigenesis, and prognosis of PDAC. This study evaluated miR-4653-3p expression and pancreatic intraepithelial neoplasia (PanIN) using in situ hybridization and the association between miR-4653-3p expression and clinicopathological factors in patients with PDAC. The miR-4653-3p target was also identified. Ninety PDAC cases, including 30 normal pancreatic ducts, 30 low-grade PanINs, and 30 high-grade PanINs were evaluated. miR-4653-3p expression was absent in normal pancreatic ducts and increased in the following order: normal pancreatic duct, low-grade PanIN, high-grade PanIN, and PDAC. High miR-4653-3p expression significantly correlated with advanced pathological T stage, lymph node metastasis, advanced UICC stage, perineural invasion, venous involvement, and shorter overall survival. Homeodomain Interacting Protein Kinase 2 (HIPK2) was identified as a miR-4653-3p target based on mRNA microarray analysis and database screening. In vitro analysis using pancreatic cancer cells showed that miR-4653-3p significantly downregulated HIPK2 expression. Immunohistochemical analysis showed that HIPK2 expression inversely correlated with miR-4653-3p expression in PDAC surgical specimens. In contrast to miR-4653-3p, HIPK2 expression decreased gradually from the normal pancreatic duct to low-grade PanIN, high-grade PanIN, and PDAC. Additionally, low HIPK2 expression was associated with shorter overall survival in patients with PDAC. These results indicate that miR-4653-3p is associated with tumorigenesis and a worse prognosis, partly by reducing HIPK2 expression.